The long-term impact of the recent rulings on Star Rating calculations
Navigating the Impact of the Star Ratings Recalculation
Learn about next steps health plans should take to secure future Star Ratings
In the first of our Ask the Experts conversations, Hayley Rogers, Consulting Actuary at Milliman, and Autri Chattopadhyay, Chief of Staff at Wellth, discuss how Medicare Advantage plans can make sense of the recent SCAN and Elevance rulings. CMS has agreed to adjust Star Ratings for plans that will benefit from the recalculation, but how should health plans think about their future Star Ratings?
During this virtual session, we will cover:
How these recalculations might influence CMS’ future policies
The steps your plan can take to secure and enhance your Star Ratings
Hayley is a Consulting Actuary who has been with Milliman since 2008. Hayley’s relevant experience includes 16 years of preparing Medicare Advantage bids, including five years certifying MA-PD bids. She also evaluates and certifies actuarial assets and liabilities as part of the annual statutory financial submissions for her Medicare clients.
She is passionate about leading research within Milliman, focusing on innovative strategies to help clients navigate new and emerging challenges. Her research on the impact of COVID-19 on the healthcare industry was recognized with the Milliman Global Health Practice Director Outstanding Service Award in 2020. Hayley continues to innovate, and is currently developing new analytic and strategic approaches to improve Medicare Star Ratings for Milliman’s clients.
As Chief of Staff, Autri works closely with the leadership team across strategy, partnerships, and operations at Wellth. Having spent his career in healthcare, Autri is passionate about solving systemic problems in healthcare and impacting the most vulnerable and highest-risk populations across Medicaid, Medicare and D-SNP.
Prior to joining Wellth, Autri was an investor at MBX Capital, an early-stage healthcare focused venture capital firm where he remains a venture partner. Before MBX, he worked as Director of Investments at FundRx, a healthcare and life sciences investment marketplace. He began his career as a strategy consultant in the life sciences sector with Frankel Group/Huron Life Sciences (now a part of Oliver Wyman).